OncoMatch/Clinical Trials/NCT07193511
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Is NCT07193511 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including AVZO-103 and Combination Agent for solid tumor cancer.
Treatment: AVZO-103 · Combination Agent — This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a monotherapy and in combination therapy to patients with locally advanced or metastatic urothelial cancer or other solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Urothelial Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Avenzo Therapeutics Recruiting Site · Orlando, Florida
- Avenzo Therapeutics Recruiting Site · Boston, Massachusetts
- Avenzo Therapeutics Recruiting Site · Myrtle Beach, South Carolina
- Avenzo Therapeutics Recruiting Site · Nashville, Tennessee
- Avenzo Therapeutics Recruiting Site · Austin, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify